Awards & Advancement

Orwin joins Array BioPharma’s board of directors

Friday, November 9, 2012 02:29 PM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs for the treatment of cancer, has appointed John A. Orwin, CEO of Affymax, to Array's board of directors as part of its continued evolution toward late-stage development and commercialization.

More... »

Insmed appoints Andrew Drechsler as CFO

Thursday, November 8, 2012 02:49 PM

Insmed, a biopharmaceutical company focused on inhaled therapeutics for serious lung diseases, has appointed Andrew Drechsler to the position of chief financial officer.

More... »

Nimbus Discovery names Lynch as executive chairman

Friday, November 2, 2012 03:04 PM

Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.

More... »

Mahoney becomes CEO and president of Boston Scientific

Friday, November 2, 2012 11:52 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, has named Michael F. Mahoney its new CEO and president. Mahoney succeeds interim CEO William H. (Hank) Kucheman. Mahoney has also been appointed to the Boston Scientific board of directors. 

More... »

ViaCyte appoints Altman to board of directors

Thursday, November 1, 2012 11:22 AM

ViaCyte, a San Diego-based regenerative medicine company developing transformative cell therapy for diabetes, as appointed Steve R. Altman to its board of directors.

More... »

Aesica wins European Outsourcing award for UCB acquisition strategy

Thursday, November 1, 2012 10:53 AM

Aesica, a global contract manufacturing organization, has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites—at Monheim and Zwickau, Germany, and Pianezza in, Italy, in 2011.

More... »

Premack joins Celtaxsys as chief technology officer

Friday, October 26, 2012 12:31 PM

Celtaxsys, a San Francisco-based, private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed life sciences technology expert, Brett A. Premack, Ph.D., as chief technology officer.

More... »

arGEN-X appoints David Lacey to supervisory board

Friday, October 26, 2012 11:12 AM

arGEN-X, a biopharmaceutical company based in The Netherlands and focused on human monoclonal antibodies from its proprietary SIMPLE Antibody platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

More... »

Former i3 CEO Bilawsky tapped to lead Precision Health Economics

Friday, October 19, 2012 02:55 PM

Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.

More... »

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »